查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1736700

全球糖化血红素 A1C 检测设备市场规模（按技术、最终用户、产品类型、区域范围和预测）

Global Hemoglobin A1C Testing Devices Market Size By Technology, By End-User, By Product Type, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

糖化血红素A1C检测设备的市场规模及预测

预计 2024 年血红素 A1C 检测设备市场规模将达到 14.5 亿美元，到 2032 年将达到 28.9 亿美元，2026 年至 2032 年的复合年增长率为 8.97%。

与血糖值仪不同，糖化血红素 (HbA1c) 检测设备并非设计用于家用检测。目前美国唯一获得 FDA 核准的家用糖化血红素 (HbA1c)检测检测套组。这与血糖仪不同，后者可以方便地在家中进行检测。

A1C Now 自检试剂套件是一种指尖采血测试，约 12 分钟即可出结果。不过，您的血液样本必须邮寄到实验室处理，结果会在几天内送达。此检验不适用于孕妇、过去三个月内输过血的人或患有某些血液疾病的人。

全球糖化血红素A1C检测设备市场动态

影响糖化血红素 A1C 检测设备市场的关键市场动态是：

关键市场驱动因素

糖尿病盛行率上升：根据国际糖尿病联盟 (IDF) 的数据，全球糖尿病患者数量正在迅速增加。最新的 IDF 糖尿病地图集估计，2019 年有 4.63 亿成年人（20-79 岁）患有糖尿病。预计到 2045 年，这一数字将上升至 7 亿。这种急剧增长是由多种因素造成的，包括人口增长、老化、都市化以及生活方式的改变，例如加工食品消费增加和体力活动减少。糖尿病盛行率的上升是糖化血红蛋白 (A1c) 检测设备市场的主要驱动力。

预防性医疗保健日益受到重视：大众对预防性医疗保健和糖尿病管理意识的不断提升，推动了糖化血红蛋白 (HbA1c) 检测设备在早期发现和介入方面的应用。政府机构和卫生组织正在进行宣传活动，向公众宣传糖尿病预防和早期发现的重要性。这些宣传活动通常强调 HbA1c 检测在识别糖尿病风险因素以及进行早期疗育以预防或延缓疾病发作方面的作用。

就地检验(POCT)：即时检测 (POCT) 设备的兴起正在彻底改变糖化血红蛋白 (HbA1c) 检测，它允许在诊所、药房甚至家中获取结果。这使得患者无需前往检查室或实验室抽血，大大提高了检测的便利性和可近性。与传统的实验室分析仪相比，即时检测 (POCT) 设备通常体积更小、更便携、更易于使用。即时检测 (POCT) 设备能够比传统的实验室分析仪更快地提供结果，通常在几分钟内即可完成，从而能够快速做出治疗决策并进行调整。

主要问题

糖化血红蛋白 (HbA1c) 检测设备和测试的费用：HbA1c 检测设备和测试的费用对某些患者来说可能是一个重大障碍，尤其是在医疗预算有限且糖尿病管理保险覆盖不足的新兴国家。这可能导致 HbA1c 检测可近性的差异、糖尿病诊断的延误，并阻碍有效的疾病管理。

准确度担忧：儘管准确性已显着提高，但仍存在一些担忧，例如血红蛋白变异和某些药物等因素可能造成干扰。这可能导致检测结果不准确、诊断延迟以及不必要的治疗调整。製造商正在不断努力提高 HbA1c 检测设备的准确性，以最大限度地减少这些干扰因素的影响。

主要趋势

专注于家用检测：对便捷易得的糖尿病管理的需求日益增长，推动了家用糖化血红蛋白 (A1c) 检测设备的发展。这些设备使患者能够在家中舒适地检测糖化血红蛋白 (HbA1c) 水平，无需频繁前往检查室或实验室。目前，家用 A1c 检测的普及程度有限，但预计未来几年将变得更加普及和完善。

与糖尿病管理系统整合：将糖化血红蛋白 (HbA1c) 检测设备整合到综合糖尿病管理系统中已成为一种趋势。这些系统将糖化血红蛋白 (HbA1c) 检测与血糖监测、持续血糖监测 (CGM) 设备、胰岛素帮浦和行动应用程式结合。这种数据整合可以更全面地了解患者的糖尿病状况，并有助于制定个人化治疗方案。此外，这些系统还可以为患者提供即时数据分析和回馈，使他们能够就糖尿病管理做出明智的决策。

目录

第一章 糖化血红素A1C检测设备全球市场介绍

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章 糖化血红素 A1C 检测设备的全球市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

5. 全球糖化血红素 A1C 检测设备市场（依技术）

  • 概述
  • 高效液相层析（HPLC）
  • 免疫测量
  • 硼酸盐亲和层析法
  • 直接酵素法检测法
  • 其他的

第六章全球糖化血红素 A1C 检测设备市场（按最终用户）

  • 概述
  • 医院
  • 诊断实验室
  • 学术和研究机构
  • 其他的

7. 全球糖化血红素 A1C 检测设备市场（依产品类型）

  • 概述
  • 桌上型装置
  • 照护现场(POC) 设备

8. 全球糖化血红素 A1C 检测设备市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他的
    • 拉丁美洲
    • 中东和非洲

第九章全球糖化血红素A1C检测设备市场的竞争格局

  • 概述
  • 各公司市场排名
  • 重点发展策略

第十章 公司简介

  • Abbott Laboratories
  • Siemens Healthineers
  • F. Hoffmann-La Roche AG
  • Danaher Corporation
  • Bio-Rad Laboratories Inc.
  • Sebia
  • ARKRAY, Inc.
  • Trinity BIoTech

第十一章 附录

  • 相关调查
简介目录
Product Code: 40143

Hemoglobin A1C Testing Devices Market Size And Forecast

Hemoglobin A1C Testing Devices Market size was valued at USD 1.45 Billion in 2024 and is projected to reach USD 2.89 Billion by 2032, growing at a CAGR of 8.97% from 2026 to 2032.

Hemoglobin A1C (HbA1c) testing devices are not designed for home testing, unlike blood glucose meters. There is currently only one FDA-approved home A1C test kit available in the United States, the A1C Now Self-Check Kit. This differs from blood glucose meters, which are readily available for home testing.

The A1C Now Self-Check Kit is a finger prick test that provides results in about 12 minutes. However, it requires that the blood sample be mailed to a lab for processing, and you will receive your results in a few days. This test is not intended for people who are pregnant, have been transfused in the past 3 months, or have certain blood conditions.

Global Hemoglobin A1C Testing Devices Market Dynamics

The key market dynamics that are shaping the Hemoglobin A1C Testing Devices Market include:

Key Market Drivers

Rising Diabetes Prevalence: Globally, the number of people with diabetes is on a sharp rise, according to the International Diabetes Federation (IDF). In their latest IDF Diabetes Atlas, they estimate that 463 million adults (aged 20-79 years) were living with diabetes in 2019. This number is projected to rise to 700 million by 2045. This dramatic increase is due to several factors, including population growth, aging, urbanization, and lifestyle changes such as increased consumption of processed foods and decreased physical activity. The rising prevalence of diabetes is a major driver of the Hemoglobin A1c Testing Devices Market.

Increased Focus on Preventive Care: Growing public awareness about preventive healthcare and diabetes management is driving the use of HbA1c testing devices for early detection and intervention. Government agencies and health organizations are launching campaigns to educate the public about the importance of diabetes prevention and early detection. These campaigns often highlight the role of HbA1c testing in identifying diabetes risk factors and enabling early intervention to prevent or delay the onset of the disease.

Point-of-Care Testing (POCT): The rise of POCT devices is revolutionizing HbA1c testing by enabling results to be obtained at clinics, pharmacies, or even at home. This eliminates the need for patients to visit a doctor's office or lab for blood draws, significantly improving convenience and access to testing. POCT devices are typically smaller, portable, and easier to use than traditional laboratory-based analyzers. They can provide results in a much shorter timeframe, often within minutes, allowing for quicker treatment decisions and adjustments.

Key Challenges:

Cost of HbA1c Testing Devices and Tests: The cost of HbA1c testing devices and tests can be a significant barrier for some patients, particularly in developing countries where healthcare budgets are limited and insurance coverage for diabetes management may be lacking. This can lead to disparities in access to HbA1c testing, potentially delaying diabetes diagnosis and hindering effective disease management.

Accuracy Concerns: While accuracy has improved significantly, some concerns remain regarding the potential for interference from certain factors such as hemoglobin variants and certain medications. This can lead to inaccurate test results, potentially causing delays in diagnosis or prompting unnecessary treatment adjustments. Manufacturers are constantly working on improving the accuracy of HbA1c testing devices to minimize the impact of these interfering factors.

Key Trends:

Focus on Home Testing: The growing demand for convenient and accessible diabetes management is driving the development of home A1c testing devices. These devices allow patients to test their HbA1c levels in the comfort of their own homes, eliminating the need for frequent visits to a doctor's office or lab. While currently limited in availability, home A1c testing is expected to become more widespread and sophisticated in the coming years.

Integration with Diabetes Management Systems: There's a trend towards integrating HbA1c testing devices with comprehensive diabetes management systems. These systems combine HbA1c testing with blood glucose monitoring, continuous glucose monitoring (CGM) devices, insulin pumps, and mobile apps. This data integration allows for a more holistic view of a patient's diabetes status and facilitates personalized treatment plans. Additionally, these systems can provide real-time data analysis and feedback to patients, empowering them to make informed decisions about their diabetes management.

Global Hemoglobin A1C Testing Devices Market Regional Analysis

Here is a more detailed regional analysis of the hemoglobin A1C Testing Devices Market:

Asia Pacific:

According to Verified Market Research, Asia Pacific is estimated to dominate the market over the forecast period. The region has the highest number of people living with diabetes globally, driven by factors like population growth, aging demographics, and increasing urbanization. This large and growing pool of potential patients fuels the demand for HbA1c testing devices.

Economic development in many Asian countries is leading to increased healthcare spending and rising disposable incomes. This creates a more favorable market for innovative medical technologies like HbA1c testing devices.

Many Asian governments are launching initiatives to address the growing burden of diabetes. These initiatives often include promoting early detection and management of diabetes, which can lead to increased adoption of HbA1c testing devices.

Manufacturers are developing more affordable HbA1c testing devices to cater to the price-sensitive markets in Asia Pacific.

Europe:

Europe has a well-established market for Hemoglobin A1c testing devices, with a strong presence of leading manufacturers and a well-developed healthcare infrastructure.

There's a growing emphasis on proactive management of chronic diseases like diabetes across Europe. HbA1c testing plays a crucial role in monitoring blood sugar control and allowing for timely adjustments to treatment plans, contributing to this focus.

Reimbursement policies play a significant role in the European market. Manufacturers need to navigate these policies to ensure that their HbA1c testing devices are covered by healthcare systems, which can influence market adoption.

European healthcare systems prioritize high-quality medical devices. This focus on accuracy and reliability can influence purchasing decisions for HbA1c testing devices.

European healthcare systems prioritize cost-effectiveness. Manufacturers need to balance technological advancements with affordability to ensure their HbA1c testing devices are financially viable for healthcare providers.

North America:

North America is a leader in developing and adopting innovative medical technologies. This trend extends to the Hemoglobin A1c Testing Devices Market, with manufacturers in North America at the forefront of developing new and improved HbA1c testing devices.

North American countries have some of the highest healthcare expenditures globally. This allows for greater investment in new technologies like HbA1c testing devices.

Public health initiatives and campaigns in North America have significantly increased awareness about diabetes and the importance of early detection. This growing awareness fuels the demand for HbA1c testing as a tool for early diagnosis and risk assessment.

The United States, in particular, has one of the highest healthcare expenditures globally. This allows for greater investment in new technologies like HbA1c testing devices, accelerating market growth.

Global Hemoglobin A1C Testing Devices Market: Segmentation Analysis

The Global Haemoglobin A1C Testing Devices Market is segmented based on Technology, End-User, Product Type, And Geography.

Haemoglobin A1C Testing Devices Market, By Technology

  • High-Performance Liquid Chromatography (HPLC)
  • Immunoassay
  • Boronate Affinity Chromatography
  • Direct Enzymatic Assay
  • Others

Based on Technology Type, the market is segmented into High-Performance Liquid Chromatography (HPLC), Immunoassay, Boronate Affinity Chromatography, Direct Enzymatic Assay, and Others. The High-Performance Liquid Chromatography (HPLC) segment is estimated to exhibit the highest growth within the apparel market due to This dominance stems from its exceptional accuracy and reproducibility in measuring HbA1c levels. HPLC separates various blood components based on their unique properties, allowing for precise isolation and quantification of HbA1c. While other technologies may be emerging, HPLC's established performance makes it the current gold standard for HbA1c testing in laboratories.

Haemoglobin A1C Testing Devices Market, By End-User

  • Hospitals
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Others

Based on End users, the market is segmented into Hospitals, Diagnostic Laboratories, Academic & Research Institutes, and Others. The hospital segment is estimated to dominate the apparel market. This is because hospitals manage a high volume of patients, including those with diabetes or at risk of developing it. HbA1c testing plays a crucial role in both diagnosing diabetes and monitoring blood sugar control in hospitalized patients. Additionally, hospitals often have the resources to invest in a wider range of HbA1c testing devices, including advanced laboratory-based analyzers and point-of-care devices for faster results.

Haemoglobin A1C Testing Devices Market, By Product Type

  • Bench-top Devices
  • Point-of-Care (POC) Devices

Based on the Product type, the market is divided into Bench-top Devices, Point-of-Care (POC) Devices. The bench-top devices segment is estimated to dominate the global market. These are laboratory-based instruments offering high accuracy and throughput, ideal for large-scale processing of blood samples in hospitals and diagnostic labs. However, the market is shifting toward Point-of-Care (POC) devices. These are smaller, portable devices designed for use in clinics, pharmacies, and even at home. POC devices offer faster turnaround times and greater convenience for patients and healthcare providers. As technology advances and affordability improves, POC devices are expected to capture a larger share of the market in the coming years.

Key Players

  • The "Hemoglobin A1C Testing Devices Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Abbott Laboratories, Siemens Healthineers, F. Hoffmann-La Roche AG, Danaher Corporation, Bio-Rad Laboratories, Inc., Sebia, Tosoh Bioscience, ARKRAY, Inc., and Trinity Biotech.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • Hemoglobin A1C Testing Devices Market Recent Developments
  • In 2024, Trivitron Healthcare introduced the NANO H5 and NANO H110, which are advanced HPLC-based diagnostic solutions for HbA1c testing that provide results in about 130 seconds.
  • In 2024, Abbott Laboratories offers the Afinion(TM) HbA1c Dx assay, a point-of-care device that delivers rapid and accurate results

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HEMOGLOBIN A1C TESTING DEVICES MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL HEMOGLOBIN A1C TESTING DEVICES MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL HEMOGLOBIN A1C TESTING DEVICES MARKET, BY TECHNOLOGY

  • 5.1 Overview
  • 5.2 High-Performance Liquid Chromatography (HPLC)
  • 5.3 Immunoassay
  • 5.4 Boronate Affinity Chromatography
  • 5.5 Direct Enzymatic Assay
  • 5.6 Others

6 GLOBAL HEMOGLOBIN A1C TESTING DEVICES MARKET, BY END-USER

  • 6.1 Overview
  • 6.2 Hospitals
  • 6.3 Diagnostic Laboratories
  • 6.4 Academic & Research Institutes
  • 6.5 Others

7 GLOBAL HEMOGLOBIN A1C TESTING DEVICES MARKET, BY PRODUCT TYPE

  • 7.1 Overview
  • 7.2 Bench-top Devices
  • 7.3 Point-of-Care (POC) Devices

8 GLOBAL HEMOGLOBIN A1C TESTING DEVICES MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East & Africa

9 GLOBAL HEMOGLOBIN A1C TESTING DEVICES MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Abbott Laboratories
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Siemens Healthineers
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 F. Hoffmann-La Roche AG
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Danaher Corporation
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Bio-Rad Laboratories Inc.
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Sebia
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 ARKRAY, Inc.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Trinity Biotech
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments

11 Appendix

  • 11.1 Related Research